# A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

> **NCT01163747** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** tocilizumab
- **DRUG:** methotrexate
- **BIOLOGICAL:** 23-Valent Pneumococcal Polysaccharide Vaccine
- **BIOLOGICAL:** Tetanus Toxoid Adsorbed Vaccine

## Key facts

- **NCT ID:** NCT01163747
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-06
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2012-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163747, "A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01163747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*